Eli Lilly came to the 44 th annual JP Morgan Healthcare Conference bolstered by a strong year. 1 While the looming patent cliff still impacts that company’s upcoming strategy, Lilly found itself in a ...
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b ...
Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics ...
Market Report by Application, Distribution Channel, Route of Administration and Company Analysis, 2025-2033" has been added ...
Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Halozyme ...
Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab ...
Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised its quarterly dividend 15% to $1.73 per share. The ...
What To Know: Novo Nordisk, one of Eli Lilly’s main competitors, announced a regulatory breakthrough for an oral weight loss drug. The FDA approved the company’s pill form of Wegovy, making it the ...
Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy according to hedge funds. On December 15, Goldman Sachs lifted its price target on Eli Lilly and Company (NYSE:LLY) to $1,145 ...
Eli Lilly (LLY) submitted an FDA application for orforglipron. The once-daily oral pill maintained weight loss after patients switched from injections. Lilly’s Zepbound achieved 20.2% average weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback